The importance of oxidized low-density lipoprotein (oxLDL) has been implicated in the process of plaque rupture. However, few previous studies demonstrated the relationship between plaque morphology and oxLDL. We evaluated the relationship between coronary plaque vulnerability assessed by optical coherence tomography (OCT) and circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL).
Introduction
Vascular inflammation and oxidative stress are considered to play essential roles in the plaque vulnerability and subsequent plaque rupture. Elevated oxidized low-density lipoprotein (oxLDL) could play critical roles in the transition from stable to vulnerable plaque. 1 Malondialdehyde-modified LDL (MDA-LDL), which is an oxLDL, can be detectable in circulating blood and has been shown to be elevated in acute coronary syndrome (ACS). 2 -5 However, few previous studies demonstrated the relationship between oxLDL and plaque vulnerability in vivo, mainly because of the lack of a sensitive method to specifically identify vulnerable plaques. Optical coherence tomography (OCT) is a recently developed intravascular modality which allows us to assess plaque morphology in patients with ACS. 6 -9 OCT clearly demonstrated the various features of vulnerable plaques, including plaque rupture, thrombus, and thin-cap fibroatheromas (TCFAs) not only in culprit, but also in non-culprit lesions in ACS. 10 Thus, the purpose of this study was to examine the association between coronary plaque vulnerability assessed by OCT and circulating MDA-LDL levels in patients with coronary artery disease.
Methods

Study population
From March 2009 to October 2010, patients undergoing coronary angiography and subsequent percutaneous coronary intervention with OCT in Social Insurance Kinan Hospital were prospectively enrolled in this study. Subjects were excluded if they had (1) a significant left main coronary artery lesion (n ¼ 1), (2) chronic total occlusion (n ¼ 1), (3) a reference vessel diameter of .4 mm (n ¼ 3), (4) extremely tortuous or heavily calcified vessels (n ¼ 1), (5) lesions with inadequate OCT images including those with massive thrombi (n ¼ 4), (6) congestive heart failure (n ¼ 1), (7) serum creatinine .1.8 mg/dL (n ¼ 1), and (8) an intercurrent infection or other inflammatory diseases (n ¼ 1). A total of 102 patients were thus included in the final analysis. There were 49 patients with stable angina pectoris (SAP) and 53 patients with ACS including 21 patients with acute myocardial infarction and 32 patients with unstable angina pectoris based on the World Health Organization criteria.
Blood samples
Blood samples were collected before coronary angiography (5 + 3 h in acute myocardial infarction (AMI) patients, 18 + 12 h in patients with unstable angina after the onset of symptoms, and in the fasting state in those with stable angina). Serum samples were separated by centrifugation immediately after blood collection. Total cholesterol, highdensity lipoprotein (HDL) cholesterol, and triglyceride levels were measured by enzymatic methods. Low-density lipoprotein (LDL) cholesterol levels were calculated by Friedwald equation.
11 Serum highsensitivity C-reactive protein (hs-CRP) concentrations were measured by a latex particle-enhanced turbidimetric immunoassay using N-assay LA CRP-S D-type Kit (Nitttobo Medical, Tokyo, Japan) on the Hitachi 7600 autoanalyzer. Serum samples for MDA-modified LDL were stored at 48C until assays were performed. Circulating MDA-modified LDL levels were measured by using enzyme-linked immunosorbent assay at SRL Co., Ltd, Tokyo, Japan, as described previously. 12, 13 In brief, diluted serum samples were added to the wells of the plates, which were coated with monoclonal antibody against MDA-LDL (ML25). ML25 recognize MDA residue but do not recognize other aldehyde modification. As ML25 is not specific for MDA-LDL, b-galactosidase-conjugated monoclonal antibody against apoB (AB16) was then added. The combination of ML25 and AB16 has been shown to recognize MDA-LDL, and 1 U/L was defined as the absorbance obtained with the primary standard at a concentration of 1 mg/L of MDA-LDL.
Coronary angiography and quantitative coronary angiographic analysis
Coronary angiography was performed with a 6F catheter via the radial approach. All patients received an intravenous bolus injection of 3000 IU of heparin and intracoronary isosorbide dinitrate (2 mg) before angiography. The culprit lesion in ACS and SAP was identified from the findings of coronary angiography corroborated with electrocardiography, nuclear stress test, or transthoracic echocardiography. If the culprit vessel had more than two lesions, the most severe proximal stenosis was considered as the culprit lesion. Coronary angiograms were reviewed separately by two independent observers unaware of the OCT findings. Reference diameter, minimal lumen diameter, and percent diameter stenosis were measured on-line with quantitative coronary angiography (QCA) by applying the Automated Coronary Analysis system (Philips Medical Systems, Leiden, the Netherlands) before coronary intervention.
OCT image acquisition and analysis
Oral aspirin (162 mg) and intravenous heparin (100 U/kg) were administered before coronary intervention. The OCT examination was performed before any intervention in ACS patients or SAP patients with a thrombolysis in myocardial infarction (TIMI) flow grade 3. In ACS patients with TIMI flow grade of 0 to 2, the culprit lesions were evaluated by OCT imaging after thrombectomy using a thrombus aspiration catheter (Thrombuster III; Kaneka Medics, Tokyo, Japan). All OCT image acquisitions were performed with the continuous flushing method. After administration of 100 -300 mg of intracoronary nitroglycerin, a 0.016-in. OCT imaging wire (ImageWire, LightLab Imaging, Westford, MA, USA) was advanced to the distal end of the culprit lesion through a microcatheter (Transit, Cordis Endovascular Systems, Miami Lakes, FL, USA). To remove the blood cells from the imaging field, dextran-40 and lactate Ringer's solution (Low Molecular Dextran L Injection, Otsuka Pharmaceutical Factory, Tokushima, Japan) was infused through the guiding catheter using a power injection (2.5 -4.5 mL/s). Motorized pullback OCT imaging was performed at a rate of 1.0 mm/s for a length of 30 mm. The images were acquired at a rate of 15 frames/s and were digitally archived in the OCT system console for off-line analysis. All OCT images were analysed by two independent investigators who were unaware of the clinical presentation and laboratory data. When discordance was present between the observers, consensus reading was obtained. The presence of TCFA, plaque rupture, or thrombus was noted. Plaque rupture was identified by the presence of fibrous cap discontinuity and a cavity formation in the plaque. A fibrous cap was identified as a signal-rich homogenous region overlying a lipid core characterized by a signal-poor region on the OCT image. The thinnest part of the fibrous cap was measured three times, and the average value was calculated. The lesion with a plaque cap thickness ,65 mm was diagnosed as TCFA. TCFA was classified as either ruptured TCFA or morphologically intact TCFA according to the presence of plaque rupture. Thrombus was identified as an irregular mass protruding into the vessel lumen.
Statistical analysis
Results are expressed as mean + SD for normally distributed variables and median [interquartile range (IQR)] for skewed variables. Categorical data are presented as numbers (%). Differences between the two groups were tested by the unpaired t-test for approximately normally distributed variables, and by the Mann-Whitney test for skewed variables. The x from non-TCFA assessed by OCT. Statistical analysis was performed using SPSS software for Windows version 11.0 (SPSS, Inc., Chicago, IL, USA). All probability values are two-sided. P-values of ,0.05 were considered statistically significant. Table 1 summarizes age, gender, conventional cardiovascular risk factors, angiographic findings, and lipid profiles in each group of patients. Patient characteristics, including age, gender, and incidence of hypertension, diabetes, smoking, and dyslipidaemia, were comparable between two groups, except that patients with ACS showed lower HDL levels. Patients with SAP had higher TIMI flow grade compared with those with ACS at initial angiogram.
Results
Patient characteristics
OCT findings
Plaque types classified by OCT findings were summarized in Table 2 . TCFAs were detected more frequently in ACS than in SAP [44 (83%) vs. 8 (16%), P , 0.001]. Plaque ruptures and thrombi were more frequently observed in ACS than in SAP [25 (47%) vs. 3 (6%), P , 0.001; 26 (49%) vs. 2 (4%), P , 0.001, respectively]. Among patients with SAP, three patients (6%) had ruptured TCFA and one (2%) had non-TCFA with thrombus. Among ACS patients, 22 (42%) had morphologically intact TCFA and 22 (42%) had ruptured TCFA with/without thrombus. Three patients (6%) with non-TCFA had thick-cap fibroatheroma with plaque rupture. Representative OCT images of morphologically intact TCFA without thrombus and ruptured TCFA are shown in Figure 1 .
Serum levels of MDA-LDL and hs-CRP
Circulating MDA-LDL levels were significantly higher in patients with ACS compared with SAP, and hs-CRP levels were higher in patients with ACS than those with SAP ( Table 1) . Regarding the levels of circulating MDA-LDL and hs-CRP levels according to baseline patient characteristics ( Table 3) , there was no significant difference except hs-CRP levels in relation to TIMI flow grade.
The MDA-LDL and hs-CRP levels were stratified according to each plaque component assessed by OCT. The levels of MDA-LDL in patients with TCFA and plaque rupture were significantly higher compared with those without. There was no significant difference in the levels of MDA-LDL according to the presence of intracoronary thrombus. The hs-CRP levels in patients with TCFA, plaque rupture, and thrombus were significantly higher than those without (Table 3) . When circulating MDA-LDL levels were categorized into low (,25th percentile, ,99 U/L), intermediate (25th to 75th percentile, 99-175 U/L), and high (.75th percentile, .175 U/L) groups, the frequency of TCFA increased significantly from patients with a low MDA-LDL level to those with a high MDA-LDL level (P , 0.001, Figure 2A) . Similar trends were observed regarding the association between the frequency of TCFA and hs-CRP (P , 0.001, Figure 2B) .
The MDA-LDL and hs-CRP levels were analysed in the subgroup of patients with SAP and those with ACS, separately. In patients presenting with SAP, the levels of MDA-LDL were significantly higher in patients with TCFA than those with non-TCFA [187 (156, 222) vs. 104 (87, 131); P , 0.001, Figure 3A ]. The patients with TCFA had a trend towards higher hs-CRP levels Figure 3B] .
In subjects presenting with ACS, the levels of MDA-LDL were not significant between patients with TCFA and those with non-TCFA [166 (142, 184) vs. 99 (79, 200); P ¼ 0.286, Figure 4A ]. The levels of hs-CRP were significantly higher in patients with TCFA than those without [1.9 (0.6, 4.6) vs. 0.4 (0.3, 0.9); P ¼ 0.015, Figure 4B ]. Among ACS patients with TCFA, subjects with ruptured TCFA (n ¼ Multivariate logistic regression analysis (Cox and Snell's R 2 ¼ 0.43) showed that MDA-LDL level (odds ratio, 1.45 per every 10-unit increment; 95% CI, 1.24-1.68; P , 0.001) and hs-CRP (odds ratio, 3.98 per log-10 increment; 95% CI, 1.47-10.7; P ¼ 0.006) were associated with the presence of TCFA (Table 4) . However, no significant correlation was found between MDA-LDL and hs-CRP (Spearman's r ¼ 0.12; P ¼ 0.23). showed 64% sensitivity and 88% specificity in patients presenting ACS.
Discussion
Coronary plaque rupture and subsequent thrombosis is the most common mechanism leading to acute myocardial infarction.
14 Rupture-prone plaques are shown to have fibrous caps ,65 mm by post-mortem evaluation. 15 The thickness of the fibrous cap is an important index of plaque morphology of vulnerable plaque and can be evaluated accurately by OCT. 16 In overall patients, circulating MDA-LDL levels were associated with the presence of TCFA assessed by OCT. Interestingly, in patients presenting with stable angina, higher levels of MDA-LDL were observed in patients with TCFA compared with those with non-TCFA. Similar trend was observed in ACS patients without plaque rupture. Oxidative modification of lipoproteins is widely accepted as a key event in the genesis of atherosclerosis. Moreover, previous studies have suggested that oxLDL stimulates matrix metalloproteinase (MMP)-1 and MMP-9 expressions in human vascular endothelial cell and in monocyte-derived macrophages 17, 18 and upregulates the expression of MMP-1 and -3 in human coronary endothelial cells through its endothelial receptor, lectin-like oxidized LDL receptor- Association of MDA-LDL levels with TCFAs et al. 21 showed the increased oxLDL production preceding the progression of atherosclerotic lesions in apolipoprotein E knockout mice. Although we do not know the time-dependent change of MDA-LDL levels, our current data provide an intriguing observation of the possible link between circulating oxLDL and TCFA. This study demonstrated that patients with ACS had higher levels of oxLDL than those with stable angina in accordance with previous study. 2 -5 The mechanism of the increased levels of MDA-LDL in ACS seems more complicated. Our data showed that the levels of MDA-LDL in ACS patients with ruptured TCFA were higher than those with morphologically intact TCFA. The release of oxLDL from atherosclerotic plaques into the circulation was suggested by Tsimikas et al. 22 who showed the temporal increase in oxLDL levels after percutaneous coronary intervention. Holvoet et al. 2 suggested that the increase of MDA-LDL in ACS may be partially explained by platelet activation subsequent to plaque rupture. Activated platelet could release aldehydes that preferentially oxidize LDL to MDA-LDL. Although monoclonal antibody against MDA-LDL used in this study recognizes only MDA modification and do not recognize other aldehyde modification, it is possible that platelet activation and coagulation may be associated with MDA-LDL levels in vivo and in vitro. Moreover, a previous post-mortem study by Ferrante et al. 23 showed that luminal thrombi overlying eroded plaques contain a higher density of myeloperoxidase-positive cells than those on ruptured plaque. As myeloperoxidase has been implicated in LDL oxidative modification, 24 thrombi superimposed on a plaque without rupture may affect the MDA-LDL levels. However, we did not observe significant differences in MDA-LDL levels according to the presence of thrombus. Further studies are needed to clarify the possible relationship between intracoronary thrombus and oxLDL. Proinflammatory stimuli promote LDL oxidative modification, and oxLDL provokes inflammation, thus oxidative stress and inflammation in arterial walls are closely linked. We investigated the association of MDA-LDL and hs-CRP levels with the presence of TCFA using ROC curve analysis. Our results showed that MDA-LDL had higher sensitivity and specificity than hs-CRP in all patients. However, the diagnostic value of MDA-LDL was less satisfactory in patients with ACS, presumably because of complicated mechanism of increased levels of MDA-LDL in ACS as mentioned above. On the other hand, the diagnostic value of hs-CRP was improved in ACS. This improvement would be partially explained by the myocardial ischaemia, as the increase in CRP levels is likely to reflect inflammation secondary to myocardial cell injury in ACS. 25 The hs-CRP cutoff value of 1.1 mg/L for ACS patients in this study was much lower than that of 3.0 mg/L used in the previous report. 26 This is supported by the fact that the value of CRP in Japanese population is much lower than in Western population. The cutoff point of hs-CRP for the prognostic assessment in Japanese population was reported to be 1.0 mg/L in both primary 27 and secondary prevention, 28, 29 which is compatible with our results.
Because plaque instability precedes ischaemic injury, circulating MDA-LDL would be a possible marker for TCFA. Further studies are needed to determine the causal relationship between the elevated levels of MDA-LDL and plaque morphology.
Several limitations of the present study need to be considered. First, because this study was cross-sectional, it is not known whether the elevation of circulating MDA-LDL in ACS represent a primary pathogenic stimulus in plaque vulnerability or mere a byproduct of other disease processes. Second, we used MDA-LDL to measure oxLDL in the present study. However, oxLDL particles have a heterogeneous population with a variety of oxidized products and diverse biological properties because of a lack of uniformity in definitions and measurement protocols. Thus, it is difficult to quantify the full range of oxLDL. Third, we did not measure the time-dependent changes in MDA-LDL levels after the onset of ACS, although previous study showed the temporal increase in oxLDL in ACS. 30, 31 Time-dependent change of the MDA-LDL levels from the onset in ACS might affect results. Fourth, the sample size in this study was relatively small and hence a large-scale study is needed. Fifth, the assessments of thrombus by OCT might be modulated by the time from the onset to OCT image acquisition, antiplatelet therapy, and thrombus aspiration before OCT examination. And the exclusion of the cases of much thrombus might introduce selection bias for the assessment of thrombus. Sixth, we could not exclude the possibility that coronary plaques and plaques in other vascular beds, remote from target lesion, might impact the results of MDA-LDL and hs-CRP levels because of the systemic pathophysiological process of plaque vulnerability. And finally, this cross-sectional study was not designed to answer the question of whether MDA-LDL levels independently predict clinical outcomes. Further studies are required to determine whether the findings of this study can be extrapolated to other population and evaluate the prognostic impacts of MDA-LDL and hs-CRP.
In conclusion, this study provides the data linking circulating oxLDL levels and plaque characteristics in patients with coronary artery disease. Circulating MDA-LDL levels might be associated with the presence of TCFA in the culprit lesion. 
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